Allan Wissner
Pfizer (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Quinazolinone synthesis and applications, Synthesis and biological activity, Synthetic Organic Chemistry Methods, Inflammatory mediators and NSAID effects
Most-Cited Works
- → Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib(2005)951 cited
- → Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase(2004)630 cited
- → Combinatorial chemoprevention of intestinal neoplasia(2000)494 cited
- → Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agent(1992)296 cited
- → Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity(2005)295 cited
- → 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity(2001)272 cited
- → Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)(2002)263 cited
- → 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth Factor Receptor Kinase and Their Bioisosteric Relationship to the 4-Anilino-6,7-dialkoxyquinazoline Inhibitors(2000)209 cited
- → The Development of HKI‐272 and Related Compounds for the Treatment of Cancer(2008)175 cited
- → Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies(2009)162 cited